CeriBell (CBLL) vs CONMED (CNMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CeriBell (CBLL) has outperformed CONMED (CNMD) over the past year, gaining 79.5% versus a gain of 8.8%. CONMED is the larger company by market cap ($1.39 billion vs $1.06 billion), about 1.3 times the size, while CeriBell is growing revenue faster (+36.1% vs +5.2%). CONMED converts more of its revenue into profit, with a net margin of 3.4% versus -60.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBLL | CNMD |
|---|---|---|
| Share price | $27.39 | $46.56 |
| Market cap | $1.06B | $1.39B |
| 1-day change | +6.37% | +0.39% |
| YTD return | +24.90% | +14.68% |
| 1-year return | +79.49% | +8.84% |
| 5-year return | — | -65.53% |
| P/E ratio (TTM) | — | 19.32 |
| Forward P/E | — | 9.80 |
| EPS (TTM) | $-1.95 | $2.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $89.06M | $1.37B |
| Revenue growth (YoY) | +36.09% | +5.18% |
| Net income (latest FY) | $-53.41M | $47.05M |
| Gross margin | 87.89% | 54.59% |
| Operating margin | -65.57% | 7.46% |
| Net margin | -59.97% | 3.42% |
| 52-week high | $28.89 | $54.80 |
| 52-week low | $14.87 | $31.44 |
| Distance from 52-week high | -5.19% | -15.04% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +15.26% | +0.58% |
| Average volume | 452.64K | 364.31K |
| Shares outstanding | 38.84M | 29.80M |
| Employees | 327 | 3,900 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBLL has outperformed CNMD by 70.7 percentage points over the past year.
- CONMED is more profitable, keeping 3.4 cents of every revenue dollar as net income versus -60.0 cents for CeriBell.
- CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +5.18%).
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,900 employees
CBLL vs CNMD FAQ
Which is bigger, CeriBell or CONMED?
CONMED (CNMD) is larger, with a market capitalization of $1.39B compared with $1.06B for CeriBell (CBLL).
Which stock has performed better over the past year, CBLL or CNMD?
CBLL returned +79.49% over the past 12 months, compared with +8.84% for CNMD (price return, excluding dividends). Past performance does not predict future results.
Are CeriBell and CONMED in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.